These findings suggest that COAD patients with high PFKFB4 expression may have a higher tendency to utilize the glycolytic pathway for metabolic biosynthesis, which could be associated with enhanced immunological responses and increased immune infiltration. The gene discussed is PFKFB4; the disease is colon adenocarcinoma.